Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact-A systematic literature review

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 2, 2015, Pages 190-194

  Carli, Linda ^a,b   Tani, Chiara ^a   Vagnani, Sabrina ^a   Signorini, Viola ^a   Mosca, Marta ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Infections; Leukopenia; Lymphopenia; Neutropenia; Systemic lupus erythematosus

Indexed keywords

COLONY STIMULATING FACTOR;

DISEASE ACTIVITY; DISEASE SEVERITY; HUMAN; INCIDENCE; INFECTION RISK; LEUKOCYTE; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; NEUTROPENIA; NEUTROPHIL COUNT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; COMORBIDITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPENIA;

COMORBIDITY; HUMANS; LEUKOPENIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPENIA; NEUTROPENIA; PREVALENCE;

EID: 84941747424     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.05.009     Document Type: Review

References (35)

1. Newman K., Owlia M.B., El-Hemaidi I., Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus-old and new. Autoimmun Rev 2013, 12:784-791.
2. Hepburn A.L., Narat S., Mason J.C. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010, 49:2243-2254.
3. Hochberg M.C. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
4. Romero-Diaz J., Isenberg D., Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic LupusInternational Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res 2011, 63(Suppl. 11):S37-S46.
5. Castrejón I., Tani C., Jolly M., Huang A., Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol 2014, 32:S-85-S-95.
6. http://www.cochrane.org/handbook.
7. http://www.prisma-statement.org.
8. Laupacis A., Wells G., Richardson W.S., Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. J Am Med Assoc 1994, 272:234-237.
9. Al-Rayes H., Al-Swailem R., Arfin M., Sobki S., Rizvi S., Tariq M. Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus 2007, 16:755-763.
10. Al Arfaj A.S., Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009, 18:465-473.
11. Dias A.M., do Couto M.C., Duarte C.C., Inês L.P., Malcata A.B. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE. Ann N Y Acad Sci 2009, 1173:103-107.
12. Jeong S.J., Choi H., Lee H.S., Han S.H., Chin B.S., Baek J.H., et al. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 2009, 41:268-274.
13. Rabbani M.A., Siddiqui B.K., Tahir M.H., Ahmad B., Shamim A., Shah S.M., et al. Systemic lupus erythematosus in Pakistan. Lupus 2004, 13:820-825.
14. Vilá L.M., Alarcón G.S., McGwin G., Bastian H.M., Fessler B.J., Reveille J.D., et al. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Care Res 2006, 55:799-806.
15. Rivero S.J., Diaz-Jouanen E., Alarçòn-Segovia D. Lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1978, 21:295-305.
16. Houman M.H., Smiti-Khanfir M., Ben Ghorbell I., Miled M. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 2004, 13:204-211.
17. Beyan E.C., Beyan C., Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology 2007, 12:257-261.
18. Nossent J.C., Swaak A.J. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991, 80:605-612.
19. Lee S.W., Park M.C., Lee S.K., Park Y.B. Adjusted neutropenia is associated with early serious infection in systemic lupus erythematosus. Mod Rheumatol 2013, 23:509-515.
20. Lertchaisataporn K., Kasitanon N., Wangkaew S., Pantana S., Sukitawut W., Louthrenoo W. An evaluation of the association of leukopenia and severe infection in patients with systemic lupus erythematosus. J Clin Rheumatol 2013, 19:115-120.
21. Merayo-Chalico J., Gómez-Martín D., Piñeirúa-Menéndez A., Santana-De Anda K., Alcocer-Varela J. Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. QJM 2013, 106:451-457.
22. Ruiz-Irastorza G., Olivares N., Ruiz-Arruza I., Martinez-Berriotxoa A., Egurbide M.V., Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11:R109.
23. Bosch X., Guilabert A., Pallarés L., Cerveral R., Ramos-Casals M., Bové A., et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006, 15:584-589.
24. Hu S.C., Lin C.L., Lu Y.W., Chen G.S., Yu H.S., Wu C.S., et al. Lymphopaenia, anti-Ro/Anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus. Acta Derm Venereol 2013, 93:314-318.
25. Ng W.L., Chu C.M., Wu A.K., Cheng V.C., Yuen K.Y. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 2006, 99:37-47.
26. Martínez-Baños D., Crispín J.C., Lazo-Langner A., Sánchez-Guerrero J. Moderate and severe neutropenia in patients with systemic lupus erythematosus. Rheumatology 2006, 45:994-998.
27. Sakai T., Hatano Y., Abe I., Ishii K., Fujiwara S. A case of an SLE patient with febrile neutropenia who experienced exacerbation of cutaneous manifestations after the administration of G-CSF. Mod Rheumatol 2013, 23:1231-1236.
28. Paliga A., Shahbazi N., Gonsalves C., Bormanis J., Padmore R. Trilineage myelodysplasia and hemophagocytosis associated with systemic lupus erythematosus. Am J Hematol 2012, 87:529-530.
29. Vasiliu I.M., Petri M.A., Baer A.N. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. J Rheumatol 2006, 33:1878-1880.
30. Hellmich B., Schnabel A., Gross W.L. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum 1999, 29:82-99.
31. Euler H.H., Harten P., Zeuner R.A., Schwab U.M. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997, 24:2153-2157.
32. Euler HH, Schwab UM, Schroeder JO. Filgrastim for lupus neutropenia. Lancet 1994;344:1513-1514.
33. Kondo H., Date Y., Sakai Y., Akimoto M. Effective simultaneous rhG-CSF and methylprednisolone "pulse" therapy in agranulocytosis associated with systemic lupus erythematosus. Am J Hematol 1994, 46:157-158.
34. Bashal F. Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J 2013, 7:87-95.
35. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42:2433-2453.